Abstract

APARICIO HERNANDEZ, R.; GARCIA LUQUE, A.; PRATS OLIVAN, P.  and  SANCHEZ LOPEZ, P.. Possitive assesment of drugs: March, April and May 2016. Sanid. Mil. [online]. 2016, vol.72, n.3, pp.200-208. ISSN 1887-8571.

The drugs assessed by the Spanish Agency for Medicines and Health Products or European Medicines Agency made public in March, April and May of 2016, and considered of interest to the healthcare profesional, are reviewed. These are positive technical reports prior to the authorization and placing on the market of the product.

Keywords : Ceftazidima y Avibactam; Zavicefta^®; Cloruro de Lutecio (177 Lu); Endolucinbeta^®; Daclizumab; Zinbryta^®; Daratumumab; Darzalex^®; Elbasvir / Grazoprevir; Zepatier^®; Emtricitabina / Rilpivirina / Tenofovir alafenamida; Odefsey^®; Fracción celular enriquecida con CD34+ autólogos que contienen células CD34+ transducidas con vector retroviral que codifica la secuencia humana ADA cADN; Strimvelis^®; Migalastat; Galafold^®; Opicapona; Ongentys^®; Polvo pancreático; Enzepi^®; Saxagliptina / Dapagliflozina; Qtern^®; Sofosbuvir/Velpatasvir; Epclusa^®; Vacuna antigripal pandémica H5N1 (viva atenuada, nasal); Vacuna antigripal pandémica H5N1 MedImmune^®.

        · abstract in Spanish     · text in Spanish     · Spanish ( pdf )